(Editor’s note: Missed the earlier ASHG recaps? Find them here! Day One Day Two) In yesterday’s blog, I talked about genetic variability and some concerns about its usefulness. So today, I attended a late evening session, “Clinical Impact of Genetic Variation,” to learn more about how these findings are being used for clinical purposes. The session was led by… Read article →
Day 2 of ASHG 2015 opened with a very interesting session on ASHG/ESHG Building Bridges, which focused on perceptions of clinical sequencing in the US and the EU. The 4-member panel included researchers from Columbia University, the US Food and Drug Administration (FDA), the Cyprus Institute of Neurology and Genetics and Our Lady’s Children’s Hospital,… Read article →
ASHG 2015 began yesterday with two great sessions. In the first, ASHG president Dr. Neil Risch reflected on the history of the organization and ASHG’s evolution over the years. In the second session, the Presidential Symposium on “Genetic Epidemiology at Scale: High Throughput Genomics Linked to Large Scale EHR systems,” Dr. Francis Collins talked about the precision… Read article →
Are you using or planning to use RNAseq in your research? If so, please help us understand your needs! Complete the global survey on RNAseq and find out how your fellow scientists are applying RNAseq technology in their research. Take the survey!
Precision medicine offers to transform patient care by targeting treatment to those with the most to gain. To date, the most significant advances have been at the DNA level. Development of RNA expression signatures as biomarkers has been more problematic. While RNA expression analysis has yielded valuable insights into the biological mechanisms of disease, RNA… Read article →